Private equity firm ChrysCapital has acquired a 70.68% controlling stake in Novartis India Ltd, a listed pharmaceutical trading and distribution company, in a deal valued at approximately ₹1,446 crore. The transaction marks ChrysCapital's first majority-controlled investment in the Indian pharmaceutical sector. Alongside the acquisition, Vikas Gupta has been appointed as the new chief executive officer of Novartis India, the company confirmed this week.
The acquisition process involved ChrysCapital purchasing the majority stake from existing shareholders, enabling it to take control of Novartis India’s operations. The firm’s appointment of Vikas Gupta as CEO signals a strategic leadership change aimed at steering the company through its next growth phase. The financial details of the deal were not fully disclosed, but the transaction value was pegged at around ₹1,446 crore, according to livemint.com.
This deal is significant as it represents ChrysCapital’s entry as a majority stakeholder in the Indian pharmaceutical market, a sector witnessing increased private equity interest due to its growth potential and essential healthcare role. Novartis India, being a key player in pharmaceutical trading and distribution, provides ChrysCapital with a platform to expand its footprint. Comparable deals in the sector have attracted attention for consolidating market positions and enhancing operational efficiencies.
Novartis India’s new leadership under Vikas Gupta is expected to focus on strengthening the company’s market presence and operational capabilities. The acquisition was officially announced on July 30, 2026, with ChrysCapital now holding a 70.68% stake in the company, marking a pivotal moment in the firm’s investment strategy within the pharmaceutical industry.